CJC-1295
Growth-hormone axis (GHRH analogue)
Status & caution. Not FDA-approved and NOT among the 12 peptides FDA advanced to PCAC review in 2026. FDA nonclinical documentation (Dec 2024) cited adverse findings including DNA damage in pituitary cells. Sold as 'research only.' Flagged in regulatory nonclinical findings; the long-acting DAC form sustains GH/IGF-1 elevation, which is exactly the kind of continuous signalling the body is not designed for.
At a glance
Indications & what it's studied for
Marketed to raise GH/IGF-1 for muscle, fat loss, recovery, and sleep. The DAC version produces a prolonged 'bleed' of GH rather than a clean pulse.
Contraindications & cautions
Cancer or cancer risk; pituitary disease; pregnancy. The sustained-elevation concern is amplified versus short-acting GHRH analogues.
Commonly reported dosing
Reported, not recommended. The following describes what appears in research literature and community use. It is not a protocol, and unapproved peptides have no validated human dosing.
Community protocols differ sharply between the no-DAC ('mod GRF') and with-DAC forms; no validated human dosing exists.
Routes of administration
Subcutaneous injection.
Don't combine with
Somatostatin analogues; combining with multiple secretagogues stacks the GH-axis risk.
Reported to stack with
Routinely paired with ipamorelin in community use; note this combines two unapproved agents with limited human safety data.
Note: "stacking" combines multiple agents and multiplies unknowns; popularity of a combination is not evidence of its safety.
What the research actually shows
Early pharmacology established the albumin-binding half-life extension; human safety data are thin, and regulators have cited unresolved nonclinical signals.
Before acting on anything here, see Safety & the grey market and how to read a COA.